Construction and Validation of a Necroptosis-Related lncRNA Signature in Prognosis and Immune Microenvironment for Glioma

Figure 5

Validation of OS and DFS in survival analysis, distribution, expressional difference, and sensitivity between high-risk and low-risk patients in TCGA. (a) Survival analysis of the 3 cohorts. (b) The risk scores for individuals. (c) The distributions of survival time and patients for risk scores. (d) Heatmap of prognostic necroptosis-related lncRNAs expression in different risk groups.